SEARCH

SEARCH BY CITATION

References

  • 1
    Global Allergy and Asthma European Network (GA2LEN). Allergy and asthma: Global Disease. Available at: http://www.ga2len.net/index.cfm?action=viewPublicPage&pageID=1678 (accessed December 14, 2006).
  • 2
    Beasley R and The International Study of Asthma and Allergies in Childhood (ISAAC) Steering Committee. Worldwide variation in prevalence of symptoms of asthma, allergic rhinoconjunctivitis, and atopic eczema: ISAAC. The International Study of Asthma and Allergies in Childhood (ISAAC) Steering Committee. Lancet 1998;351:12251232.
  • 3
    Burney P, Chinn S, Jarvis D, Luczynska C, Lai E. On behalf of the European Community Respiratory Health Survey. Variations in the prevalence of respiratory symptoms, self-reported asthma attacks, and use of asthma medication in the European Community Respiratory Health Survey (ECRHS). Eur Respir J 1996;9:687695.
  • 4
    Asher MI, Montefort S, Björkstön B, Lai CKW, Strachan DP, Weiland SK, Williams H. and The ISAAC Phase Three Study Group. Worldwide time trends in the prevalence of symptoms of asthma, allergic rhinoconjunctivitis, and eczema in childhood: ISAAC Phases One and Three repeat multicountry cross-sectional surveys. Lancet 2006;368:733743.
  • 5
    Reed SD, Lee TA, McCrory DC. The economic burden of allergic rhinitis: a critical evaluation of the literature. Pharmacoeconomics 2004;22:345361.
  • 6
    Fokkens WJ. Who should treat patients with seasonal allergic rhinitis? Allergy 2002;57:469471.
  • 7
    Leynaert B, Neukirch C, Liard R, Bousquet J, Neukirch F. Quality of life in allergic rhinitis and asthma: a population-based study of young adults. Am J Respir Crit Care Med 2000;162:13911396.
  • 8
    European Academy of Allergology and Clinical Immunology. The impact of allergic rhinitis on quality of life and other airway diseases. Summary of a European conference. Allergy 1998;53(Suppl. 41):731.
  • 9
    Juniper EF, Guyatt GH, Griffith LE, Ferrie PJ. Interpretation of rhinoconjunctivitis quality of life questionnaire data. J Allergy Clin Immunol 1996;98:843845.
  • 10
    Meltzer EO, Jalowayski AA, Vogt K, Iezzoni D, Harris AG. Effect of desloratadine therapy on symptom scores and measures of nasal patency in seasonal allergic rhinitis: results of a single-center, placebo-controlled trial. Ann Allergy Asthma Immunol 2006;96:363368.
  • 11
    Berger WE, Schenkel EJ, Mansfield LE. Desloratadine Study Group. Safety and efficacy of desloratadine 5 mg in asthma patients with seasonal allergic rhinitis and nasal congestion. Ann Allergy Asthma Immunol 2002;89:485491.
  • 12
    Nayak AS, Schenkel E. Desloratadine reduces nasal congestion in patients with intermittent allergic rhinitis. Allergy 2001;56:10771080.
  • 13
    Canonica GW, Tarantini F, Compalati E, Penagos M. Efficacy of desloratadine in the treatment of allergic rhinitis: a meta-analysis of randomized, double-blind, controlled trials. Allergy 2007;62:359366.
  • 14
    Heithoff K, Meltzer EO, Mellars L, Salmun M. Desloratadine improves quality of life in patients with seasonal allergic rhinitis. J Allergy Clin Immunol 2000;104(Suppl.):S383; abstract 1121.
  • 15
    Satish U, Streufert S, Dewan M, Voort SV. Improvements in simulated real-world relevant performance for patients with seasonal allergic rhinitis: impact of desloratadine. Allergy 2004;59:415420.